Plus, news about Hyundai Bioscience, Clear Scientific and Terns Pharmaceuticals:
Xencor prices $175M offering: The Pasadena, CA-based biotech made the financing move after announcing drug candidates in autoimmune diseases earlier in the week. — Kyle LaHucik
Viridian’s $150M offering: The Waltham, MA-based company kicked off the stock sale the same day as disclosing Phase 3 data in thyroid eye disease. — Kyle LaHucik
Hyundai Bioscience touts broad-spectrum antiviral: The Korean biotech said its candidate, Xafty, has shown promise against several viral infections in animal, cell and clinical studies. The niclosamide reformulation, which was developed using Hyundai’s proprietary drug delivery technology, is currently in a Phase 3 trial for high-risk Covid-19 patients. — Ayisha Sharma
Clear Scientific reveals safety data for overdose drug: The Cambridge, MA-based biotech said CS-1103 demonstrated a “favorable safety and tolerability profile” in a Phase 1 trial of 32 healthy volunteers. The company is planning to advance the small molecule sequestrant into Phase 2 development for meth and fentanyl overdose, set to start in early 2025. — Ayisha Sharma
Terns Pharmaceuticals upsizes share sale: The drugmaker priced a $150 million offering after originally planning to raise $125 million on the back of Phase 1 obesity data revealed earlier this week. — Kyle LaHucik